CAS: 174635-69-9 - 3-methyl-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
Formula:C26H24N2O
InChI:InChI=1S/C26H24N2O/c1-3-22(19-12-6-4-7-13-19)28-26(29)24-18(2)25(20-14-8-5-9-15-20)27-23-17-11-10-16-21(23)24/h4-17,22H,3H2,1-2H3,(H,28,29)/t22-/m0/s1
InChI key:InChIKey=MQNYRKWJSMQECI-QFIPXVFZSA-N
SMILES:O=C(NC(C=1C=CC=CC1)CC)C=2C=3C=CC=CC3N=C(C=4C=CC=CC4)C2C
- Synonyms:
- 3-Methyl-2-phenyl-N-[(1S)-1-phenylpropyl]-4-quinolinecarboxamide
- 4-Quinolinecarboxamide, 3-methyl-2-phenyl-N-(1-phenylpropyl)-, (S)-
- 4-Quinolinecarboxamide, 3-methyl-2-phenyl-N-[(1S)-1-phenylpropyl]-
- Sb 222200
4-Quinolinecarboxamide, 3-methyl-2-phenyl-N-[(1S)-1-phenylpropyl]-
CAS:174635-69-9
Formula:
C26H24N2O
Purity:
98%
Color and Shape:
Solid
Molecular weight:
380.4816
Ref: IN-DA001ZUA
10mg | 92.00 € | ||
25mg | 162.00 € | ||
50mg | 196.00 € | ||
100mg | 331.00 € | ||
250mg | 529.00 € |
Estimated delivery in United States, on Monday 25 Nov 2024
SB 222200
CAS:174635-69-9
Formula:
C26H24N2O
Purity:
>98.0%(HPLC)
Color and Shape:
White to Light yellow powder to crystal
Molecular weight:
380.49
Ref: 3B-B6551
10mg | 209.00 € |
Estimated delivery in United States, on Friday 29 Nov 2024
SB-222200
CAS:174635-69-9
SB-222200 is a selective, reversible, and competitive antagonist of the human NK-3 receptor(Ki=4.4 nM).
Formula:
C26H24N2O
Purity:
97.13%
Color and Shape:
Solid
Molecular weight:
380.48
Ref: TM-T16849
1mg | 39.00 € | ||
5mg | 73.00 € | ||
10mg | 99.00 € | ||
25mg | 236.00 € | ||
50mg | 451.00 € | ||
100mg | 644.00 € | ||
1mL*10mM (DMSO) | 87.00 € |
Estimated delivery in United States, on Monday 2 Dec 2024
(S)-3-Methyl-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide
CAS:174635-69-9
(S)-3-Methyl-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide is a research chemical with potential antiviral properties. It belongs to the class of …
Formula:
C26H24N2O
Purity:
Min. 95%
Molecular weight:
380.49 g/mol
Ref: 3D-ZGA63569
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Tuesday 7 Jan 2025